Protocol: CRI Registry (CRIPR) Targeted Adverse Event(ADV)
|
|
- Evan Atkinson
- 5 years ago
- Views:
Transcription
1 Page 1 of 19 Targeted Adverse Event(ADV) Version: 1.1; Adverse Event: 1-Malignancy 2-Avascular necrosis 3-Slipped capital femoral epiphyses 4-Intracranial hypertension 5-Other serious adverse event 6-Other adverse event Adverse Event Date: _ 1. If malignancy, please specify diagnosis: 2. If avascular necrosis or slipped capital femoral epiphyses, record the following: Onset: gfedc 1-Initial gfedc 2-Recurring X-ray confirmation: gfedc 1-No gfedc 2-Yes Bone scan confirmation: gfedc 1-No gfedc 2-Yes 3. If intracranial hypertension, record the following: Opening CSF pressure: (xxx) mmh2o Headache: gfedc 1-No gfedc 2-Yes Papilledema: gfedc 1-No gfedc 2-Yes Nausea & vomiting: gfedc 1-No gfedc 2-Yes Visual changes: gfedc 1-No gfedc 2-Yes 4. If Serious adverse event, please specify: 5. If Other adverse event, please specify:
2 Page 2 of 19 Targeted Adverse Event(ADV Page 2) Adverse Event: 1-Malignancy 2-Avascular necrosis 3-Slipped capital femoral epiphyses 4-Intracranial hypertension 5-Other serious adverse event 6-Other adverse event Adverse Event Date: _ 6. Intensity: 7. Outcome: 1-Mild 2-Moderate 3-Severe 4-Life-threatening 1-Severe or permanent disability 2-Death 3-Neither 8. Treatment required? gfedc 1-No gfedc 2-Yes Hospitalization: gfedc 1-No gfedc 2-Yes Medication: gfedc 1-No gfedc 2-Yes Surgery: gfedc 1-No gfedc 2-Yes Other treatment: gfedc 1-No gfedc 2-Yes If Other treatment, specify: 9. Was patient receiving growth hormone at the time of adverse event? If receiving growth hormone, record the following: a. Type: b. Route c. Frequency: gfedc 1-No gfedc 2-Yes 1-Nutropin 2-Protropin 3-Humatrope 4-Nutropin Depot 9-Other 1-Subcutaneous 2-Intraperitoneal 1-Daily 2-Every other day 3-Three times/week 4-Six times/week 5-Weekly 6-Every other week 7-Monthly 9-Other
3 Page 3 of 19 Targeted Adverse Event(ADV Page 3) Adverse Event: 1-Malignancy 2-Avascular necrosis 3-Slipped capital femoral epiphyses 4-Intracranial hypertension 5-Other serious adverse event 6-Other adverse event Adverse Event Date: _ d. Dose: (x.xx) mg/dose e. Dosage of growth hormone was: 1-Unchanged 2-Reduced 3-Held 4-Discontinued f. If dose changed, provide date: (mm/dd/yyyy) Did the adverse event abate? gfedc 1-No gfedc 2-Yes If Yes, record date: (mm/dd/yyyy) g. Was growth hormone reintroduced? gfedc 1-No gfedc 2-Yes If Yes, did the adverse event recur? gfedc 1-No gfedc 2-Yes If Yes, when? (mm/dd/yyyy) 10. Relationship to growth hormone: 1-Not related- never received 2-Not related 3-Possible 4-Probable 11. Comments:
4 Page 4 of 19 Targeted Adverse Event(ADV Page 4) Adverse Event: 1-Malignancy 2-Avascular necrosis 3-Slipped capital femoral epiphyses 4-Intracranial hypertension 5-Other serious adverse event 6-Other adverse event Adverse Event Date: _ Signature: Date:
5 Page 5 of 19 Chronic Renal Insufficiency Termination(CRI) Version: 1.1; Date of termination: (mm/dd/yyyy) 2. Patient height at termination: (xxx.x) cm 3. Check to unlock and change unit of measurements: Serum creatinine: CU SI Units gfedc gfedc mg/dl gfedc µmol/l 4. Reason for termination: If Other, specify: (xx.x) (xxxx.x) 1-Patient was transplanted 2-Patient initiated maintenance dialysis 3-Patient regained renal function 4-Patient died 9-Other 5. Comments:
6 Page 6 of 19 Chronic Renal Insufficiency Termination(CRI Page 2) Signature: Date:
7 Page 7 of 19 Chronic Renal Insufficiency Status(CRS) Version: 1.1; Visit Number: Date of examination: (mm/dd/yyyy) PHYSICAL DATA 2. Weight: (xxx.x) kg 3. Height: (xxx.x) cm 4. Tanner Stage: Pubic hair: Unknown Breast: 6-Unknown 1-Pre-puberty (<=3 cc) 2-Early-puberty (>3-6 cc) 3-Mid-puberty (>6-10 cc) 4-Late puberty (>10-15 cc) 5-Adult (>15 cc) Testicular size: 6-Unknown 5. Are anthropometric measures available? gfedc 1-No gfedc 2-Yes If Yes, indicate: a. Mid arm circumference: (xx.x) cm b. Tricep skin fold thickness: (xx.x) mm 6. Blood pressure: (xxx) / (xxx) mm Hg 7. Check to unlock and change units of measurement: Serum creatinine: CU SI Units gfedc gfedc mg/dl gfedc µmol/l (xx.x) (xxxx.x)
8 Page 8 of 19 Chronic Renal Insufficiency Status(CRS Page 2) Visit Number: Hematocrit: CU SI Units gfedc % gfedc VF BUN: CO 2 : Inorganic phosphorus: Calcium: Albumin: Alkaline phophatase: (xx.x) (.xxx) (xxx) (xx.x) (xx) (xx) (xx.x) (xx.x) (xx.x) (x.xx) (xx.x) (xx) (xxxx) (xx.xx) gfedc mg/dl gfedc mmol/l gfedc meq/l gfedc mmol/l gfedc mg/dl gfedc mmol/l gfedc mg/dl gfedc mmol/l gfedc g/dl gfedc g/l gfedc IU/mL gfedc µkat/l
9 Page 9 of 19 Chronic Renal Insufficiency Status(CRS Page 3) Visit Number: Hemoglobin: CU SI Units gfedc g/dl gfedc g/l (xx.xx) (xx.xx) 8. Most recent parathyroid hormone: 1-Less than 2x upper normal limit 2-Greater than 2x upper normal limit 9-Unknown Medication Data 9. Is the patient receiving erythropoietin? gfedc 1-No gfedc 2-Yes a. Type: 1-Epogen 2-Procrit 3-Aranesp 9-Other b. Route: 1-Subcutaneous 2-Intraperitoneal 3-Intravenous c. Frequency: 1-Daily 2-Every other day 3-Three times/week 4-Six times/week 5-Weekly 6-Every other week 7-Monthly 9-Other d. Units/dose: 10. Is the patient receiving human growth hormone? gfedc 1-No gfedc 2-Yes a. Type: 1-Nutropin 2-Protropin 3-Humatrope 4-Nutropin Depot 9-Other b. Frequency: 1-Daily 2-Three times/week 3-Two times/week 4-Weekly 5-> Weekly
10 Page 10 of 19 Chronic Renal Insufficiency Status(CRS Page 4) Visit Number: c. Dose: 11. Concomitant Drug Therapy a. Anticonvulsant: gfedc 1-No gfedc 2-Yes b. Antihypertensives: gfedc 1-No gfedc 2-Yes If Yes, number of drugs: (x) c. Prophylactic antibiotics: gfedc 1-No gfedc 2-Yes d. Sevelamer hydrochloride: gfedc 1-No gfedc 2-Yes e. Alkali therapy: gfedc 1-No gfedc 2-Yes f. Immunosuppressives: gfedc 1-No gfedc 2-Yes 1. Prednisone: 1-No 2-Yes, qd 3-Yes, qod Dose: (xxx.x) mg/day 2. Other immunosuppressives: 1-Cyclosporine 2-Cyclophosphamide 3-Mycophenolate mofetil 4-Sirolimus 5-Chlorambucil 6-Tacrolimus 9-Other g. Lipid lowering agents: gfedc 1-No gfedc 2-Yes h. 1,25-dihydroxy Vitamin D (oral): gfedc 1-No gfedc 2-Yes i. Other Vitamin D compounds: gfedc 1-No gfedc 2-Yes j. Iron (oral): gfedc 1-No gfedc 2-Yes k. Iron (IV): gfedc 1-No gfedc 2-Yes l. Parenteral nutrition: gfedc 1-No gfedc 2-Yes m. Supplemental enteral nutrition: 1-Oral gfedc 1-No gfedc 2-Yes 2-NG If Yes, specify: 3-Gastrostomy
11 Page 11 of 19 Chronic Renal Insufficiency Status(CRS Page 5) Visit Number: n. Calcium carbonate: gfedc 1-No gfedc 2-Yes o. Calcium acetate: gfedc 1-No gfedc 2-Yes p. Other calcium supplements: gfedc 1-No gfedc 2-Yes Events Data If this is the initial CRI Status form, has patient ever had the event? If this is not the initial CRI Status form, has the patient had the event since the last report? 12. Urologic surgery: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 13. Orthopedic surgery: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 14. Urinary tract infection: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 15. Hip x-ray: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown a. If Yes, left hip: 1-Normal 2-Slipped capital femoral epiphyses 3-Avascular necrosis 9-Other b. Right hip: 1-Normal 2-Slipped capital femoral epiphyses 3-Avascular necrosis 9-Other 16. Seizures: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 17. Renal biopsy: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 18. Fluid and electrolyte abnormalities: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 19. Blood transfusions: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown If Yes, number of episodes: (x) Education Data 20. Has patient completed high school education? gfedc 1-No gfedc 2-Yes If No: 1-Attends school full time 2-Attends school part-time 3-Receives home schooling only 4-Not attending school, medically capable 5-Not attending school, medically incapable 6-Not of school age
12 Page 12 of 19 Chronic Renal Insufficiency Status(CRS Page 6) Visit Number: Hospitalization Data Omit for initial CRI Status Form 21. Total days hospitalized since last report: (xxx) 22. Number of hospitalizations since last report: (xx) Reasons for hospitalization: a. Infection: gfedc 1-No gfedc 2-Yes b. Hypertension: gfedc 1-No gfedc 2-Yes c. Other cardiovascular: gfedc 1-No gfedc 2-Yes 23. Comments: Signature: Date:
13 Page 13 of 19 Patient Death(DTH) Version: 1.1; Date of death: (mm/dd/yyyy) 2. Cause of death: 01-Infection, viral 02-Infection, bacterial 03-Infection, not specified 04-Cancer/malignancy 05-Cardiopulmonary 06-Hemorrhage 07-Recurrence of original renal disease 08-Dialysis-related complications *Additional Options Available If other, specify cause of death: 3. Graft status at death: 4. Comments: 1-Functioning 2-Non-functioning 3-Not applicable Signature: Date:
14 Page 14 of 19 Lost to Follow Up(LTF) Version: 1.1; Date lost to follow up: (mm/dd/yyyy) 2. Reason for loss: 1-Patient moved to nonparticpating center 2-Unable to locate patient 3-Patient refused further follow up 4-Parent refused further follow up 5-Patient transferred to adult program 9-Other If Other, specify: 3. Graft status at loss: 4. Comments: 1-Functioning 2-Non-functioning 3-Not applicable Signature: Date:
15 Page 15 of 19 CRIPRA(ENR) Version: 1.1; Enter the date of CRI Initiation to register this participant into the CRI Registry: (mm/dd/yyyy) 2. Patient weight at enrollment: (xxx.x) kg 3. Patient height at enrollment: (xxx.x) cm Check to unlock and change unit of measurement: gfedc 4. CU SI Units Serum Creatinine: gfedc mg/dl gfedc µmol/l (xx.x) (xxxx.x) To qualify for the CRI Registry patients must have a creatinine clearance of less than or equal to 75 ml/ min /173 m 3, based on the Schwartz formula: Creatinine Clearance: Patients who have received maintenance dialysis or who have been transplanted do not qualify for the CRI Registry.
16 Page 16 of 19 CRIPRA(ENR Page 2) Signature: Date:
17 Page 17 of 19 Registration(DEM) Version: 1.1; Date of birth: (mm/dd/yyyy) 2. Race/ethnicity: 1-White 2-Black 3-Hispanic 9-Other 3. Gender: gfedc 1-Male gfedc 2-Female 4. Primary renal diagnosis: 01-Aplastic/hypoplastic/dysplastic kidneys 02-Obstructive uropathy 03-Syndrome of agenesis of abdominal musculature (Prune Belly) 04-Polycystic kidney disease 05-Medullary cystic disease/juvenile nephronophthisis 06-Familial nephritis - Alport's Syndrome 07-Cystinosis 08-Oxalosis *Additional Options Available If Other, specify diagnosis: 5. Biopsy or nephrectomy confirmation of diagnosis: gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 6. Maternal Paternal Education Score: 0-No formal education 1-Grade 6 or less 2-Grades Grades 10 or more without diploma 4-Grade 12 (High school graduate) 5-Some college/ business/ vocational 6-College degree 7-Graduate work *Additional Options Available 0-No formal education 1-Grade 6 or less 2-Grades Grades 10 or more without diploma 4-Grade 12 (High school graduate) 5-Some college/ business/ vocational 6-College degree 7-Graduate work *Additional Options Available 7. Insurance Information: Does patient have Medicaid? gfedc 1-No gfedc 2-Yes gfedc 9-Unknown Does patient have supplemental private insurance? gfedc 1-No gfedc 2-Yes gfedc 9-Unknown 8. Has patient been transplanted prior to registration: gfedc 1-No gfedc 2-Yes 9. Total number of prior transplants: (x) 10. Has patient ever received maintenance dialysis? 1-No 2-Yes, hemodialysis 3-Yes, peritoneal dialysis 4-Yes, both If Yes, specify date of first maintenance dialysis: (xx) Month/ (xxxx) Year
18 Page 18 of 19 Registration(DEM Page 2) 11. ABO (record for Transplant and Dialysis participants): 1-A 2-B 3-O 4-AB gfedc gfedc gfedc gfedc 12. Histocompatibility data of recipient Record for transplant participants: HLA-A A (xx) A (xx) HLA-B HLA-DR B (xx) B (xx) DR (xx) DR (xx) If assay performed but an allele was not determined, enter '99' Signature: Date:
19 Additional Selection Options Page 19 of 19 DTH: Cause of death: 09-Other, specify 10-Unknown DEM: Primary renal diagnosis: 09-Congenital nephrotic syndrome 10-Focal segmental glomerulosclerosis 11-Membranoproliferative glomerulonephritis - Type I 12-Membranoproliferative glomerulonephritis - Type II 13-Membranous nephropathy 14-Idiopathic crescentic glomerulonephritis 15-Chronic glomerulonephritis 16-Pyelonephritis/interstitial nephritis 17-Reflux nephropathy 18-SID w/sle nephritis 19-SID w/henoch-schonlein purpura nephritis 20-SID w/berger's nephritis (IgA) 21-SID w/wegener's granulomatosis 22-SID w/other 23-Wilms' tumor 24-Renal infarct 25-Diabetic glomerulonephritis 26-Sickle cell nephropathy 27-Hemolytic uremic syndrome 28-Drash syndrome 30-Unknown 99-Other, specify DEM: Education Score Maternal 9-Unknown
Targeted Adverse Event (ADV)
North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.
More informationAccess Revision (ACC)
North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Registry Sequence: Date of Access Revision: Access Revision (ACC) Web Version: 1.0; 1.3; 06-20-13 HEMODIALYSIS
More informationProtocol: 1st Dialysis Sequence (DIALYA)
Page 1 of 32 North American Pediatric Renal Trials Collaborative Studies Production Release 5.0 [$sitecode] User: Registry Sequence: Date of Access Revision: Access Revision (ACC) Web Version: 1.0; 1.3;
More informationTargeted Adverse Event (ADV)
North American Pediatric Renal Trials Collaborative Studies Production Release 14.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0; 06-20-13 1.
More informationTargeted Adverse Event (ADV)
Page 1 of 35 North American Pediatric Renal Trials Collaborative Studies Production Release 5.0 [$sitecode] User: Adverse Event: Adverse Event Date: Targeted Adverse Event (ADV) Web Version: 1.0; 2.0;
More informationNorth American Pediatric Renal Trials Collaborative Studies Production Release Registration (DEM) Web Version: 1.0; 1.
Registration (DEM) Web Version: 1.0; 1.4; 06-20-13 1. Does your site participate in the NAPRT CS Registries? 1- No 2- Yes 2. Date of birth: (mm/dd/yyyy) 3. Race/ethnicity: 4. Gender: 1-Male 2-Female 5.
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2010 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE I INTRODUCTION 1 II
More informationNAPRTCS Annual Transplant Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2014 Annual Transplant Report This is a privileged communication not for publication. TABLE OF CONTENTS PAGE II TRANSPLANTATION Section
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 27 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 2006 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationNorth American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report. Renal Transplantation. Chronic Renal Insufficiency
North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) 2005 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationNAPRTCS Annual Report
North American Pediatric Renal Trials and Collaborative Studies NAPRTCS 28 Annual Report Renal Transplantation Dialysis Chronic Renal Insufficiency This is a privileged communication not for publication.
More informationESRD Dialysis Prevalence - One Year Statistics
Age Group IL Other Total 00-04 12 1 13 05-09 5 2 7 10-14 15 1 16 15-19 55 2 57 20-24 170 10 180 25-29 269 14 283 30-34 381 9 390 35-39 583 14 597 40-44 871 20 891 45-49 1,119 20 1,139 50-54 1,505 35 1,540
More informationChapter 8: ESRD Among Children, Adolescents, and Young Adults
Chapter 8: ESRD Among Children, Adolescents, and Young Adults The number of children beginning end-stage renal disease (ESRD) care decreased by 6% in 2014, totaling 1,398 (Figure 8.1.a). 9,721 children
More information3/5/18. Background. Registry Reports. Dialysis Registry Update and Future Directions
Dialysis Registry Update and Future Directions Annabelle N. Chua, MD March 4, 2018 Background Founded in 1987 as a transplant registry Expanded registry to include dialysis (1992) and CKD (1994) Patient
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 8: Pediatric ESRD 1,462 children in the United States began end-stage renal disease (ESRD) care in 2013. 9,921 children were being treated for ESRD on December
More informationTHE KIDNEY AND SLE LUPUS NEPHRITIS
THE KIDNEY AND SLE LUPUS NEPHRITIS JACK WATERMAN DO FACOI 2013 NEPHROLOGY SIR RICHARD BRIGHT TERMINOLOGY RENAL INSUFFICIENCY CKD (CHRONIC KIDNEY DISEASE) ESRD (ENDSTAGE RENAL DISEASE) GLOMERULONEPHRITIS
More informationAppendix G Coding: Ethnicity, EDTA Primary Renal Diagnoses, EDTA Causes of Death and Treatment Timeline Modality Codes
Coding: Ethnicity, EDTA Primary Renal Diagnoses, EDTA Causes of Death and Treatment Timeline Modality Codes G1: Ethnicity coding Ethnicity data is recorded in the clinical information systems in the individual
More information2015 Children's Mercy Hospitals and Clinics. All Rights Reserved.
Growth van Stralen KJ, et al., Kidney Int, 2014 Blood Pressure Management van Stralen KJ, et al., Kidney Int, 2014 Sodium Losses on PD Infants might need higher UF rate per BSA as compared to adults to
More informationCKD FOR INTERNISTS. Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College
CKD FOR INTERNISTS Dr Ahmed Hossain Associate professor Medicine Sir Salimullah Medical College INTRODUCTION In 2002, the National Kidney Foundation s Kidney Disease Outcomes Quality Initiative(KDOQI)
More informationCase Report 17-Year-Old Boy with Renal Failure and the Highest Reported Creatinine in Pediatric Literature
Case Reports in Pediatrics Volume 2015, Article ID 703960, 4 pages http://dx.doi.org/10.1155/2015/703960 Case Report 17-Year-Old Boy with Renal Failure and the Highest Reported Creatinine in Pediatric
More informationESRD Mortality. Causes of CKD in Children. Causes of Late Graft Failure. 5-Year Allograft Survival. All-cause mortality rates, 2005, by age
North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Causes of CKD in Children Founded in 1992 78 participating centers in Canada & U.S. 16,339 CKD patients age 0 18 years 9,506 renal
More informationChapter 7: ESRD among Children, Adolescents, and Young Adults
Chapter 7: ESRD among Children, Adolescents, and Young Adults The one-year end-stage renal disease (ESRD) patient mortality among the 0-4 year age group has declined approximately 41.6% over the past decade.
More informationBK Viral Infection and Malignancy in Renal Transplantation ~A Case History~
BK Viral Infection and Malignancy in Renal Transplantation ~A Case History~ Mariko Toyoda, MD Department of Nephrology, Japanese Red Cross Kumamoto Hospital Statement of Disclosure The author does not
More informationChronic Kidney Disease (CKD) Stages. CHRONIC KIDNEY DISEASE Treatment Options. Incident counts & adjusted rates, by primary diagnosis Figure 2.
Chronic Kidney Disease (CKD) Stages Stage 1 GFR > 90 (evidence of renal disease) Stage 2 GFR 60-89 Stage 3 GFR 30-59 Stage 4 GFR 15-29 Stage 5 GFR
More informationISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES ALDO E CELE DACCO
ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI CENTRO MARIO DI NEGRI RICERCHE INSTITUTE CLINICHE FOR PHARMACOLOGICAL PER LE MALATTIE RESEARCH RARE CLINICAL RESEARCH CENTER ALDO E FOR CELE RARE DACCO DISEASES
More informationCHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 2007
CHAPTER 2 NEW PATIENTS COMMENCING TREATMENT IN 27 Stephen McDonald Leonie Excell Hannah Dent NEW PATIENTS ANZDATA Registry 28 Report Figure 2.1 Annual Intake of New Patients 23-27 (Number Per Million Population)
More informationVariable Included. Excluded. Included. Excluded
Table S1. Baseline characteristics of patients included in the analysis and those excluded patients because of missing baseline serumj bicarbonate levels, stratified by dialysis modality. Variable HD patients
More informationCIBMTR Center Number: CIBMTR Recipient ID: RETIRED. Today s Date: Date of HSCT for which this form is being completed:
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Date Received: Registry Use Only Today s Date: Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic,
More informationERROR CORRECTION FORM
Juvenile Idiopathic Arthritis Pre-HSCT Data Sequence Number: Registry Use Only Date of HSCT for which this form is being completed: HSCT type: autologous allogeneic, allogeneic, syngeneic unrelated related
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr (Mr) Rohan Malek Dr Wong Hin Seng Dr Fan Kin Sing Dr Rosnawati Yahya Dr S Prasad Menon Dr Tan Si
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT HISTOPATHOLOGIC DISORDERS AFFECTING THE ALLOGRAFT OTHER THAN REJECTION RECURRENT DISEASE DE NOVO DISEASE TRANSPLANT GLOMERULOPATHY Glomerular Non-glomerular
More informationChapter 1. Incidence of End Stage Kidney Disease. Contents:
Chapter 1 Incidence of End Stage Kidney Disease Contents: Incidence of End Stage Kidney Disease 1-1 Stock and Flow 1-2 Incident patients 1-3 Incident Rates 1-3 Late Referral 1-7 Co-Morbidities 1-9 Primary
More informationPediatric GU Dysfunction
Pediatric GU Dysfunction Assessment of pediatric renal function Signs and symptoms Laboratory tests Radiological tests Nursing considerations Psychosocial and developmental considerations GU Disorders
More informationCase Presentation Turki Al-Hussain, MD
Case Presentation Turki Al-Hussain, MD Director, Renal Pathology Chapter Saudi Society of Nephrology & Transplantation Consultant Nephropathologist & Urological Pathologist Department of Pathology & Laboratory
More informationRECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT. J. H. Helderman,MD,FACP,FAST
RECURRENT AND DE NOVO RENAL DISEASES IN THE ALLOGRAFT J. H. Helderman,MD,FACP,FAST Vanderbilt University Medical Center Professor of Medicine, Pathology and Immunology Medical Director, Vanderbilt Transplant
More informationCHAPTER 14. Renal Transplantation
15th Report of the Malaysian RENAL TRANSPLANTATION CHAPTER 14 Renal Transplantation Editor: Dr. Goh Bak Leong Expert Panel: : Dato Dr. Dato Zaki Dr. Morad Zaik Morad Mohd (Chair) Zaher (Chair) Dr. Goh
More informationRENAL FAILURE IN CHILDREN Dr. Mai Mohamed Elhassan Assistant Professor Jazan University
RENAL FAILURE IN CHILDREN Dr. Mai Mohamed Elhassan Assistant Professor Jazan University OBJECTIVES By the end of this lecture each student should be able to: Define acute & chronic kidney disease(ckd)
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Goh Bak Leong
CHAPTER 5 RENAL TRANSPLANTATION Editor: Dr Goh Bak Leong Expert Panel: Dr Goh Bak Leong (Chair) Dato Dr Zaki Morad Mohd Zaher Dato Dr (Mr) Rohan Malek Dr Fan Kin Sing Dr Lily Mushahar Dr Lim Soo Kun Dr
More informationWhat Your Kidneys Do and What Happens When They Fail
Patient Education Chapter 2 Page 1 What Your Kidneys Do and What Happens When They Fail Objectives: 1. Understand basic kidney functions. 2. Understand symptoms of uremia and some treatments used for it.
More informationPROs for Drug Development. Melanie Blank, MD
PROs for Drug Development in Chronic Kidney Disease Melanie Blank, MD Disclaimer The views expressed here represent my opinions and do not necessarily represent the views of the FDA. Overview Stagnation
More informationFinal Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List
OPTN/UNOS Minority Affairs Committee Descriptive Data Request Final Report: Update on Prior Living Donors Who Were Subsequently Placed on the Waiting List Prepared for: Minority Affairs Committee Meeting
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Membranous nephropathy role of steroids GUIDELINES
Membranous nephropathy role of steroids Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES There is currently no data to support the use of short-term courses of
More informationPERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
PERITONEAL DIALYSIS CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE CORRECTIONS
More informationNephrotic syndrome minimal change disease vs. IgA nephropathy. Hadar Meringer Internal medicine B Sheba
Nephrotic syndrome minimal change disease vs. IgA nephropathy Hadar Meringer Internal medicine B Sheba The Case 29 year old man diagnosed with nephrotic syndrome 2 weeks ago and complaining now about Lt.flank
More informationi. Where is the participant seen?
PFU01 method used: Phone/in-person interview 1 Enter PIP # here: Online survey 2 Enter Web # here: Initials of person completing form: Date Form Completed: / / Form Version: 03 / 01 / 18 Is the participant
More informationPFIZER INC. PROTOCOL TITLE: Growth hormone therapy in short children after renal transplantation for chronic renal failure in Germany.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationRaDaR Inclusion and Exclusion Criteria. Diagnosis Inclusion Criteria Exclusion Criteria. Alport Syndrome definite or probable
Alport Syndrome and Type IV collagenopathies APRT Deficiency Alport Syndrome definite or probable Alport carrier definite or probable Thin basement membrane nephropathy APRT Deficiency confirmed Abolished
More informationCHAPTER 4. Paediatric Renal Biopsies
2nd Report of the Malaysian Registry of Renal Biopsy 2008 PAEDIATRIC RENAL BIOPSIES CHAPTER 4 Paediatric Renal Biopsies Lee Ming Lee Lim Yam Ngo Lynster Liaw Susan Pee Wan Jazilah Wan Ismail Yap Yok Chin
More informationTNU QUIZ. Affiliation: 1. Presence of the following may indicate non-diabetic kidney disease in a patient with type 2 diabetes mellitus:
TNU QUIZ Name: Affiliation: Print, Answer and Deliver it to the registration desk on Thursday 8 th November 2018 before 11 am 1. Presence of the following may indicate non-diabetic kidney disease in a
More informationAdditional file 2: Details of cohort studies and randomised trials
Reference Randomised trials Ye et al. 2001 Abstract 274 R=1 WD=0 Design, numbers, treatments, duration Randomised open comparison of: (45 patients) 1.5 g for 3, 1 g for 3, then 0.5 to 0.75 g IV cyclophosphamide
More informationDisorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome.
Disorders of the kidney. Urine analysis. Nephrotic and nephritic syndrome. Azotemia and Urinary Abnormalities Disturbances in urine volume oliguria, anuria, polyuria Abnormalities of urine sediment red
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Rosnawati Yahya. Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng.
CHAPTER 5 Editor: Roswati Yahya Expert Panels: Hooi Lai Seong Ng Kok Peng Suryati Binti Yakaob Wong Hin Seng Contents 5. Stock and Flow of Rel Transplantation Stock and Flow Transplant Rates 5.2 Recipients
More informationREGISTRATION PATIENT DETAILS
PATIENT DETAILS Person completing form: (please print) FOR REGIONAL REFERRAL CENTER USE ONLY Registration: Approved Date: / / Not approved RRC telephone contact with primary MD: Date: / / Reviewers Signature:
More informationRenal Disease. Please refer to the assignment page Three online modules TBLs
Renal Disease Please refer to the assignment page Three online modules TBLs 1 Renal Embryology 2 Lab Tests UA CBC Enzymes Creatinine Creatinine clearance Ammonia Abs C Bx 3 BUN Creatinine Creatinine Clearance
More informationWhat Your Kidneys Do
UW MEDICINE PATIENT EDUCATION What Your Kidneys Do And what happens with kidney disease Class Goals 1. Understand what kidneys do. 2. Understand symptoms of uremia. 3. Know the common causes of kidney
More informationAN APPROACH TO HEMATURIA. Dr Saima Ali
AN APPROACH TO HEMATURIA Dr Saima Ali Definition Microscopic hematuria hematuria is defined as the presence of 5 or more RBCs per high-power field in 3 of 3 consecutive centrifuged specimens obtained at
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationRENINE Annual Report 2015
RENINE Annual Report 2015 T. Hoekstra, M.H. Hemmelder, F.J. van Ittersum In cooperation with the sectie Registratie (Registration division) of the Nederlandse Federatie voor Nefrologie (NfN; Dutch federation
More informationMr PA. Clinical assessment of hydration. Poor urine output Sunken eyes Moistness of mucosa Cool peripheries Reduction in weight Postural hypotension
X Anthony Warrens Mr PA 54 years old Previously well Went to Thailand Developed serious diarrhoea and vomiting two days before coming home 24 hours after return, still unwell GP found: urea 24 mmol/l creatinine
More informationNATIONAL QUALITY FORUM Renal EM Submitted Measures
NATIONAL QUALITY FORUM Renal EM Submitted Measures Measure ID/ Title Measure Description Measure Steward Topic Area #1662 Percentage of patients aged 18 years and older with a diagnosis of CKD ACE/ARB
More informationIN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006
IN-CENTER HEMODIALYSIS (HD) CLINICAL PERFORMANCE MEASURES DATA COLLECTION FORM 2006 PATIENT IDENTIFICATION [Before completing please read instructions at the bottom of this page and on pages 5 and 6] MAKE
More informationPractice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome
Page 1 of 16 Practice Patterns and Outcomes of ACTHar use in Children with Nephrotic Syndrome MANUAL OF OPERATIONS VERSION 1.0 March 10, 2016 Page 2 of 16 STUDY PERSONNEL CONTACT INFORMATION Principal
More informationThe University of Arizona Pediatric Residency Program. Primary Goals for Rotation. Nephrology
The University of Arizona Pediatric Residency Program Primary Goals for Rotation Nephrology 1. GOAL: Understand the general pediatrician's role in diagnosis and management of hypertension in children.
More informationIrish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012
Irish Practice Nurses Association Annual Conference Tullamore Court Hotel OCTOBER 6 th 2012 Susan McKenna Renal Clinical Nurse Specialist Cavan General Hospital Renal patient population ACUTE RENAL FAILURE
More informationKidney Transplantation
Kidney Transplantation Current Kidney Transplantation Department of Surgery Yonsei University Wonju College of Medicine Kim Myoung Soo M.D. ysms91@wonju.yonsei.ac.kr http://gs.yonsei.ac.kr Current Kidney
More informationPatient Education Kidney Early Education Program (KEEP) Chapter 2 bjectives: Overview 1. Understand what kidneys do. 2. Understand symptoms
Patient Education (KEEP) Chapter 2 What Your Kidneys Do And what happens when they fail Objectives: 1. Understand what kidneys do. 2. Understand symptoms of uremia and some ways to treat it. 3. Know the
More informationPFIZER INC. Study Centre: One centre from Hungary enrolled subjects in this study
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationElevated Serum Creatinine, a simplified approach
Elevated Serum Creatinine, a simplified approach Primary Care Update Creighton University School of Medicine. April 27 th, 2018 Disclosure Slide I have no disclosures and have no conflicts with this presentation.
More informationB. PANITUMUMAB DOSE LEVEL 0 No dose reduction 1 Level -1 2 Level Other, specify in comments for this cycle
Radiation Therapy Oncology Group Phase II Study Pre-operative Chemo- Radiation + Panitumumab for Potentially Operable Lung Cancer Concurrent Summary Form AMENDED DATA YES INSTRUCTIONS: Submit all pages
More informationChapter 15: Report of the Paediatric Renal Registry 1999
Chapter 15: Report of the Paediatric Renal Registry 1999 Prepared by Dr M Lewis Introduction In parallel with the creation of the National Renal Registry, the British Association for Paediatric Nephrology
More informationSCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND 2015
Scottish Renal Registry Report SECTION N SCOTTISH REAL BIOPSY REGISTRY: SURVEY OF NATIVE KIDNEY BIOPSY IN SCOTLAND All centres in Scotland were able to provide date of birth, sex (except centre), indication
More informationChapter IX. Pediatric End Stage Renal Disease. Incidence of Reported Pediatric ESRD
Annual Data Report Chapter IX T his chapter examines the incidence, prevalence, modalities of treatment, and survival outcomes specific to the national pediatric ESRD population. Children with advanced
More informationWhat is meant by Thrombotic Microangiopathy (TMA)?
What is meant by Thrombotic Microangiopathy (TMA)? Thrombotic Microangiopathy (TMA) is a group of disorders characterized by injured endothelial cells, microangiopathic hemolytic anemia (MAHA), with its
More information2014 /2018 ERA-EDTA PRD Code ERA-EDTA PRD code 1996 ERA-EDTA. SNOMED CT concept identifier Convert ERA-EDTA Primary Renal Diagnosis (PRD) Term
Convert Primary Renal Diagnosis (PRD) Term ERA_EDTA diagnosis 3380 901.1.C 90 Acute kidney injury Acute Renal Failure 14669001 Miscellaneous renal disorders 3398 901.2.C 90 Acute kidney injury due to hypovolaemia
More informationEFFECTIVE SHARE CARE AGREEMENT
Specialist details Patient identifier Name: Tel: EFFECTIVE SHARE CARE AGREEMENT For the specialist use of Erythropoietin Stimulating Agent (ESA) Therapy (formerly known as EPO) for the correction of Anaemia
More information(7) VITAL SIGNS (8) LEVEL OF CONSCIOUSNESS (9) MENTAL STATUS (10) SPEECH (11) VISION (12) FUNDUS (PAPILLEDEMA)
Radiation Therapy Oncology Group Phase II CNS Lymphoma Follow-Up Form RTOG Study No. 1114 Case # Amended Data Yes INSTRUCTIONS: Submit this form as indicated in the protocol. All dates need to be recorded
More informationCHAPTER 5 RENAL TRANSPLANTATION. Editor: Dr Rosnawati Yahya
CHAPTER 5 Editor: Dr Rosnawati Yahya Expert Panels: Dr Rosnawati Yahya Dr Ng Kok Peng Dr Suryati Binti Yakaob Dr Mohd Zaimi Abd Wahab Dr Yee Seow Ying Dr Wong Hin Seng Contents 5. Stock and Flow of Renal
More informationChronic Kidney Disease
Chronic Kidney Disease Presence of kidney damage or decreased kidney function for three or more months, - necessary to distinguish CKD from acute kidney disease. Ascertained either by kidney biopsy or
More informationCHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation)
CHECK LIST FORM-MONTH 27 (Please note Month 27 is from enrolment not randomisation) Participant Initials: Date of Birth: Were the following forms completed for this visit? Follow Up Form Done t Done BVASWG
More informationThanks to our Speaker!
Thanks to our Speaker! Poyyapakkam R. Srivaths, MD, MS Medical Director of Pheresis Services Pediatric Renal Section at Texas Children s Hospital Texas Children s Hospital - Houston, Texas Chronic Kidney
More informationChapter IV. Incidence and Causes of Treated ESRD. Methods
Annual Data Report Chapter IV Incidence and Causes of Treated ESRD T he statistics in this chapter show a continued increase in the annual incidence rate of newly treated ESRD in the United States. The
More informationDIABETES MELLITUS. Kidney in systemic diseases. Slower the progression: Pathology: Patients with diabetes mellitus are prone to other renal diseases:
Kidney in systemic diseases Dr. Badri Paudel The kidneys may be directly involved in a number of multisystem diseases or secondarily affected by diseases of other organs. Involvement may be at a prerenal,
More informationSpecial Challenges and Co-Morbidities
Special Challenges and Co-Morbidities Renal Disease/ Hypertension/ Diabetes in African-Americans M. Keith Rawlings, MD Medical Director Peabody Health Center AIDS Arms, Inc Dallas, TX Chair, Internal Medicine
More informationNon-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document.
ERYTHROPOIESIS-STIMULATING AGENTS (ESAs) Epoetin alfa (Epogen, Procrit ) Darbepoetin alfa (Aranesp ) Methoxy polyethylene glycol (PEG) epoetin-beta (Mircera ) Non-Discrimination Statement and Multi-Language
More informationEpidemiology of CKD in Children
Epidemiology of CKD in Children Ali Düzova, M.D. Hacettepe University Faculty of Medicine Pediatric Nephrology and Rheumatology Unit Ankara CKD Course 03 June 2011, İstanbul Aim & Plan Causes of CKD in
More informationSCI.RWDSING GLOXERULONEPHRITIS (FSGN) OF CHILDHOOD. Jerry XcCauley, X.D. Andreas G. Tzakis, X.D. John J. Fung, X.D., Ph.D. satoru Todo, M.D.
~TEKEHT WITH FK 506 OF STEROID RESISTENT FOCAL /106 SCI.RWDSING GLOXERULONEPHRITIS (FSGN) OF CHILDHOOD Jerry XcCauley, X.D. Andreas G. Tzakis, X.D. John J. Fung, X.D., Ph.D. satoru Todo, M.D. Thomas E.
More informationGlomerular pathology in systemic disease
Glomerular pathology in systemic disease Lecture outline Lupus nephritis Diabetic nephropathy Glomerulonephritis Associated with Bacterial Endocarditis and Other Systemic Infections Henoch-Schonlein Purpura
More informationGOOD MORNING. Welcome Applicants! Friday, October 31, (Happy Halloween!)
GOOD MORNING Welcome Applicants! Friday, October 31, 2014 (Happy Halloween!) PREP QUESTION A 14-year-old girl has had 3 days of new, unremitting headache associated with vomiting and awakening from sleep
More informationSELECTED ABSTRACTS. All (n) % 3-year GS 88% 82% 86% 85% 88% 80% % 3-year DC-GS 95% 87% 94% 89% 96% 80%
SELECTED ABSTRACTS The following are summaries of selected posters presented at the American Transplant Congress on May 5 9, 2007, in San Humar A, Gillingham KJ, Payne WD, et al. Review of >1000 kidney
More informationWiskott-Aldrich Registry Data Collection Form Patient Identification: Patient Name (first, middle, last)
Patient Identification: Patient Name (first, middle, last) Patient s USIDNET Registry Number assigned after online enrollment Date of Birth / / (mm/dd/yyyy) or Year of Birth Gender: male [ ], female [
More informationProceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009
www.ivis.org Proceedings of the 34th World Small Animal Veterinary Congress WSAVA 2009 São Paulo, Brazil - 2009 Next WSAVA Congress : Reprinted in IVIS with the permission of the Congress Organizers STAGED
More informationPediatric Kidney Transplantation
Pediatric Kidney Transplantation Vikas Dharnidharka, MD, MPH Associate Professor Division of Pediatric Nephrology Conflict of Interest Disclosure Vikas Dharnidharka, MD, MPH Employer: University of Florida
More informationChapter 22: Hematological Complications
Chapter 22: Hematological Complications 22.1: Perform a complete blood count at least (Not Graded): daily for 7 days, or until hospital discharge, whichever is earlier; two to three times per week for
More informationPatient enrolment details CKDOD registry
Patient enrolment details CKDOD registry Personal Information Date of enrolment D D Date of birth D D Gender Descent Height cm m History of smoking Y N U Date of first diagnosis of CKD D D Primary Cause
More informationREACH Risk Evaluation to Achieve Cardiovascular Health
Dyslipidemia and transplantation History: An 8-year-old boy presented with generalized edema and hypertension. A renal biopsy confirmed a diagnosis of focal segmental glomerulosclerosis (FSGS). After his
More information17 th Budapest Nephrology School August, 2010 TEST
17 th Budapest Nephrology School 26 31 August, 2010 TEST AGE: GENDER: COUNTRY: 1) Which of the followings are true? 1. Hypoadiponectinemia can predispose to hypertension? 2. Hyperadiponectinemia can predispose
More informationBK virus infection in renal transplant recipients: single centre experience. Dr Wong Lok Yan Ivy
BK virus infection in renal transplant recipients: single centre experience Dr Wong Lok Yan Ivy Background BK virus nephropathy (BKVN) has emerged as an important cause of renal graft dysfunction in recent
More informationDEPARTMENT OF HEALTH AND HUMAN SERVICES CENTERS FOR MEDICARE & MEDICAID SERVICES OMB No
DEPARTMENT OF HEALTH AND HUMAN SERVICES Form Approved CENTERS FOR MEDICARE & MEDICAID SERVICES OMB No. 0938-0046 1. Name (Last, First, Middle Initial) END STAGE RENAL DISEASE MEDICAL EVIDENCE REPORT MEDICARE
More informationRENINE year report 2016
RENINE year report 216 T. Hoekstra, F.J. van Ittersum and M.H. Hemmelder In cooperation with the sectie Registratie (Registration division) of the Nederlandse Federatie voor Nefrologie (NfN; Dutch federation
More information